Imatinib
Mucosal Melanoma
Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Mucosal Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Melanoma Institute Australia | Phase 3 | BB |
Tyrosinase Peptide University of Southern California | Phase 3 | BB |
INTERFERON ALFA-2B Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | B |
Ifa Craig L Slingluff, Jr | Phase 2 | B |
Polyiclc Fred Hutchinson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →